Wild-Type p53 Protein Enhances APR-246-Induced Cytotoxicity in Acute Myeloid Leukemia and Normal Hematopoietic Stem/Progenitor Cells
John B. Cart, David Zhu, Lucas Norris, Sadhna O. Piryani, Li-Chan Chang, Christine E. Eyler, Chang-Lung Lee · 2026
Read Wild-Type p53 Protein Enhances APR-246-Induced Cytotoxicity in Acute Myeloid Leukemia and Normal Hematopoietic Stem/Progenitor Cells by John B. Cart, David Zhu, Lucas Norris, Sadhna O. Piryani, Li-Chan Chang, Christine E. Eyler, Chang-Lung Lee (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13257158.txt.
Description
John B. Cart and co-authors report a 2026 leukemia study with a warning about a p53-reactivating drug. APR-246 was built to restore broken p53 in cancer cells. The team asked whether normal p53 changes how the drug kills cells, using matched leukemia lines.
Cells lacking p53 survived the drug far better than cells with normal or mutated p53. Lowering p53 in two other leukemia lines also reduced killing. Normal blood stem cells from humans and mice lost colony-forming ability under the drug when p53 was present. Loss of working p53 cut both reactive oxygen output and programmed cell death. Oncologists should note that healthy stem cells may share the risk. Patient selection and dosing studies will need to weigh that harm carefully.
Catalog record
| CREATOR | John B. Cart, David Zhu, Lucas Norris, Sadhna O. Piryani, Li-Chan Chang, Christine E. Eyler, Chang-Lung Lee |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |